Wharton’s Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View

Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, wh...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2021-08, Vol.13 (9), p.1336
Main Authors: Muñoz-Domínguez, Noelia, Roura, Santiago, Prat-Vidal, Cristina, Vives, Joaquim
Format: Article
Language:English
Subjects:
biomanufacturing
Blood & organ donations
Bone marrow
Cardiac function
cardiac tissue engineering
clinical translation
Extracellular vesicles
Heart attacks
Heart failure
Laboratories
mesenchymal stromal cells
myocardial infarction
Pore size
Retention
Review
Severe acute respiratory syndrome coronavirus 2
Umbilical cord
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, which is in fact the major goal for effective primary care. In this context, we largely investigated novel cell and TE tissue engineering therapeutic approaches for cardiac repair, particularly using multipotent mesenchymal stromal cells (MSC) and natural extracellular matrices, from pre-clinical studies to clinical application. A further step in this field is offered by MSC-derived extracellular vesicles (EV), which are naturally released nanosized lipid bilayer-delimited particles with a key role in cell-to-cell communication. Herein, in this review, we further describe and discuss the rationale, outcomes and challenges of our evidence-based therapy approaches using Wharton’s jelly MSC and derived EV in post-MI management.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics13091336